Patents by Inventor Celina Castuma

Celina Castuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccines for the prevention of infections with
    Patent number: 9623102
    Abstract: A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and/or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 ?g per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
    Type: Grant
    Filed: March 25, 2014
    Date of Patent: April 18, 2017
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECHNICAS (CONICET), UNIVERSIDAD NACIONAL DE LA PLATA, INIS BIOTECH LLC
    Inventors: Daniela Hozbor, Daniela Bottero, María Emilia Gaillard, Eugenia Zurita, Maximiliano Omazabal, Darío Flores, Agustina Errea, Griselda Moreno, Martin Rumbo, Erika Bartel, Celina Castuma
  • VACCINES FOR THE PREVENTION OF INFECTIONS WITH BORDETELLA
    Publication number: 20160038582
    Abstract: A vaccine for the prevention of infections with Bordetella, comprising at least outer membrane vesicles (OMVs) of B. parapertussis, excipients and/or adjuvants. Bordetella may be, for example, B. pertussis or B. parapertussis. The vaccine can comprise adjuvants, for example, aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. In another preferred embodiment, the vaccine for the prevention of infections with Bordetella comprises at least outer membrane vesicles (OMVs) of B. pertussis and the lipopolysaccharide of B. parapertussis, excipients and/or adjuvants. The vaccine can comprise between 3 to 20 ?g per dose of OMVs from B. pertussis and between the amount equivalent to 107 and 1010 bacteria per dose of lipopolysaccharide of B. parapertussis. The adjuvant can be aluminum hydroxide and other immunogens such as tetanus toxoid, diphtheria toxoid, or combinations thereof. The Tdap vaccine exhibits cross activity.
    Type: Application
    Filed: March 25, 2014
    Publication date: February 11, 2016
    Inventors: Daniela HOZBOR, Daniela BOTTERO, María Emelia GAILLARD, Eugenia ZURITA, Maximiliano OMAZABAL, Darío FLORES, Agustina ERREA, Griselda MORENO, Martin RUMBO, Erika BARTEL, Celina CASTUMA
  • Synthetic liposomes for enhanced uptake and delivery
    Patent number: 5512295
    Abstract: Liposomes are prepared comprising a polyhydroxybutyrate calcium polyphosphate complex which provides for uptake of a desired component, particularly nucleotides and nucleic acids. The charged species may be introduced into the lumen of a liposome by incubating liposomes with a solution of the component of interest for sufficient time to provide for introduction of the component into the lumen of the liposome, followed by washing at diminished temperatures. The resulting liposomes may then be used as vehicles for delivery of the lumen component.
    Type: Grant
    Filed: November 10, 1994
    Date of Patent: April 30, 1996
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Arthur Kornberg, Celina Castuma